EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Khavinson Bioregulators
Khavinson bioregulators are nine ultrashort peptides—two to four amino acids each—developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as part of a 50-year research program into organ-specific bioregulatory peptides. This is the only cluster on Peptidings built entirely around one researcher’s body of work.
The theory is ambitious: ultrashort peptides enter cell nuclei, bind to DNA promoter regions, and reactivate genes silenced by aging. The evidence is entirely single-source. No compound in this cluster has been independently replicated in a Western laboratory. One (Thymogen) is a registered Russian pharmaceutical. The other eight have no controlled human trials.
Cluster at a Glance
|
9 Compounds |
1 Pilot Data |
8 Preclinical |
1 Registered Drug (Russia) |
775 Publications (Single Source) |
|
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
BLUF: Bottom Line Up Front
The Khavinson bioregulators are the most unusual compounds on Peptidings. They come from a 50-year Soviet/Russian research program with 775 publications, six approved pharmaceuticals in Russia, and a theoretical framework that proposes ultrashort peptides as natural gene regulators. The theory is not pseudoscience—there are real data, real patents, and real approved drugs. But virtually all of that evidence was produced by one institutional network, published primarily in Russian-language journals, and has never been independently replicated or subjected to Western regulatory scrutiny. One compound (Thymogen) is a registered Russian pharmaceutical. The other eight have zero controlled human trials. Vendors are selling all nine aggressively. If you are evaluating these compounds, the question is not whether any individual study is valid—it is whether you trust an entire evidence ecosystem that has never been stress-tested outside its country of origin.
In This Article
Compounds in This Cluster
All 9 compounds in the Khavinson Bioregulators cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 3
The Immune Bioregulators
Two thymic dipeptides—the most studied compounds in the Khavinson family, both targeting the immune system.
Group 2 of 3
The Metabolic Bioregulators
Organ peptides targeting the pancreas and blood vessels—where bioregulation meets metabolic medicine.
|
|
Group 3 of 3
The Organ-Specific Bioregulators
Five peptides, five organs—liver, prostate, testes, bladder, and the question of how far organ specificity can go.
|
|
|
||||||||||||
|
|
How These Bioregulators Relate
All nine compounds share a single theoretical framework: ultrashort peptides interact with DNA promoter regions to reactivate age-silenced genes in specific organs. Four of the nine—Livagen, Pancragen, Prostamax, and Testagen—share the same first three amino acids (Lys-Glu-Asp) and differ only at position four. The claim is that this single-residue substitution redirects each peptide to a different organ. This is the “KED subfamily,” and the specificity question it raises is central to evaluating the entire paradigm.
Three additional Khavinson compounds are covered in Cluster C (Longevity & Anti-Aging): Epitalon (the telomerase-activating tetrapeptide), Pinealon (the brain-targeted tripeptide), and Thymalin (the thymus extract that preceded all the synthetic bioregulators). Together with the nine compounds here, they represent the full scope of Khavinson’s 50-year research program.
| Shared Mechanism | Compounds |
|
Chromatin Decondensation Physical interaction with condensed chromatin to expose silenced gene promoter regions—the core mechanism claim of the entire bioregulation theory. |
Livagen, Vilon, Prostamax, Testagen |
|
Immune Modulation Thymic peptide regulation of T-cell differentiation, cytokine profiles, and immune senescence. |
Thymogen, Vilon |
|
Metabolic / Glucose Regulation Pancreatic beta-cell function support and glucose homeostasis in diabetic animal models. |
Pancragen |
|
Vascular Endothelial Protection Sirtuin-1 upregulation and oxidative stress reduction in endothelial cells—a cardiovascular aging target. |
Vesugen |
|
Hepatoprotection Liver-targeted peptides with chromatin and histological endpoints in animal models. |
Livagen, Ovagen |
Plain English
Four of these peptides are nearly identical molecules—same first three amino acids, different fourth. The theory says swapping one amino acid at the end changes which organ the peptide targets: liver, pancreas, prostate, or testes. No published study has demonstrated how this targeting mechanism works at the molecular level.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.